Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcoma
NCT02659020Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2016
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of olaratumab in soft tissue sarcoma (STS), sponsored by Eli Lilly and Company. Started Mar 2016; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02659020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659020.